The Contribution of Commonly Diagnosed Genetic Disorders to Small for Gestational

2 Age Birth and Subsequent Morbidity and Mortality in Preterm Infants

- 4 Miles Bomback, MPH, <sup>1</sup> Selin Everett, BS, <sup>2</sup> Alex Lyford, PhD, <sup>3</sup> Rakesh Sahni, MD, <sup>4</sup> Faith Kim,
- MD.<sup>4</sup> Caitlin Baptiste, MD.<sup>2</sup> Joshua E. Motelow, MD, PhD,<sup>5</sup> Veeral Tolia, MD,<sup>6,7,8</sup> Reese Clark, 5
- MD,6 Thomas Hays, MD, PhD4 6
- 8 <sup>1</sup> Feinberg School of Medicine, Northwestern University, Chicago
- 9 <sup>2</sup> Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia
- 10 University Medical Center, New York City
- <sup>3</sup> Middlebury College, Department of Mathematics, Middlebury, Vermont 11
- 12 <sup>4</sup> Division of Neonatology, Department of Pediatrics, Columbia University Irving Medical Center,
- 13 New York City

1

3

7

- 14 <sup>5</sup> Division of Critical Care and Hospital Medicine, Department of Pediatrics, Columbia University
- 15 Medical Center, New York City
- 16 <sup>6</sup> The Pediatrix Center for Research, Education, Quality and Safety, Sunrise, Florida
- <sup>7</sup> Division of Neonatology, Department of Pediatrics, Baylor University Medical Center, Dallas, 17
- 18 Texas

20

21

24

- <sup>8</sup> Pediatrix Medical Group, Dallas, Texas 19
- Corresponding Author: Thomas Hays, th2712@cumc.columbia.edu, 622 West 168th S. Suite PH 22
- 23 17W-303, New York, New York, 10032
- 25 Word Count:

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

**Abstract Objective:** Preterm infants born small, vs. appropriate for gestational age (SGA, AGA) are at greater risk for morbidity and mortality. The contribution of genetic disorders to preterm SGA birth, morbidity, and mortality is unknown. We sought to determine the association between genetic disorders and preterm SGA birth, and the association between genetic disorders and morbidity or mortality within preterm SGA infants. We hypothesized that genetic disorders were significantly associated with both. Study Design: This was a retrospective multicenter cohort study of 409 339 infants, born 23–33 weeks' gestation between 2000 and 2020. The odds of preterm SGA (vs AGA) birth, and the odds of severe morbidity or mortality within SGA preterm infants were determined for infants with genetic disorders, after adjusting for known risk factors. Results: Genetic disorders were present in 3.0 and 1.3% of SGA and AGA preterm infants respectively; genetic disorders conferred an aOR (95% CI) of 2.06 (1.92, 2.21) of SGA birth. Genetic disorders were present in 4.3 of preterm SGA infants with morbidity or mortality and 2.1% of preterm SGA infants that did not experience morbidity or mortality. Genetic disorders conferred an aOR (95% CI) of 2.12 (2.66, 3.08) of morbidity or mortality. **Conclusions:** Genetic disorders are strongly associated with preterm SGA birth, morbidity, and mortality. Clinicians should consider genetic testing of preterm SGA infants, particularly in the setting of other comorbidities or anomalies. Prospective, genomic research is needed to clarify the contribution of genetic disorders to disease in this population.

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Introduction Preterm infants experience a profound burden of morbidity and mortality, and small for gestational age (SGA) birth is one of the strongest clinical risk factors for poor outcomes. 1-9 SGA is defined as birth weight less than the 10<sup>th</sup> percentile or two standard deviations below mean for gestational age and sex based on estimates of population distributions. 10-13 The mechanism(s) by which SGA birth confers clinical risk are largely unknown. Known factors including impaired metabolic reserve explain only a fraction of these outcomes. 14 Although there are known risks for SGA birth, including maternal, placental, infectious, genetic, and environmental factors, the etiology of SGA birth is poorly understood. Known risks include maternal. 14-16 The overall contribution of genetic disorders to preterm SGA birth is unknown. Fetal growth restriction (FGR) and continued poor fetal growth often impacts the decision to prematurely deliver a fetus. Multiple studies have found genetic disorders associated with FGR. 17,18 Higher rates of aneuploidy and copy number variants are found in FGR, particularly when presenting before 32 weeks' gestation or accompanied by other fetal anomalies. 19,20 Metanalysis of exome and genome sequencing for FGR demonstrated single gene disorders in 4% of isolated FGR and 30% of FGR accompanied by other anomalies. <sup>17</sup> Genetic disorders have been shown to contribute to morbidity and severe mortality in related populations as well. Genetic disorders have been found in 6% of stillbirths, 10% of fetal structural anomalies, and in 20% of cohorts of pediatric critical illness or perinatal disease. 21-26 Given the burden of illness experienced by preterm SGA infants, emerging evidence that genetic disorders cause FGR and SGA, and evidence that genetic disorders cause critical illness in related populations, we sought to determine the contribution of commonly diagnosed

genetic disorders to preterm SGA birth, morbidity, and mortality. The Pediatrix Clinical

Datawarehouse (CDW) contains detailed health records of these infants, including the presence
of genetic disorders diagnosed during standard clinical care.

## Materials/Subjects and Methods:

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

This study was approved by the institutional review board of Columbia University with a waiver for informed consent. This was a retrospective multicenter cohort study using the Pediatrix CDW. The CDW includes records from approximately 400 community and academic NICUs (levels I–IV) in 35 US states and Puerto Rico, which provided care to approximately 20% of preterm infants born in the United States during the study period. Data was entered by clinicians using admission, progress, and discharge notes, as well as results from laboratory, imaging, and other diagnostic studies. These data were then extracted, consolidated, and processed to populate the CDW.<sup>27</sup> Data included demographic and maternal characteristics, diagnoses made by clinicians (genetic disorders, morbidities), and hospital disposition (mortality, discharge home, or transfer). The results of negative test results, including for genetic disorders, were not available. Records of 409 399 infants born from 23 to 33 weeks' gestation, discharged from 2000 to 2020 were extracted. Data from NICU admission to discharge were collected. Birth weight was normalized within the cohort by gestational age and sex. Cases were excluded if these data were missing. Infants were classified as SGA for normalized birth weight below the 10<sup>th</sup> percentile or as appropriate for gestational age (AGA) at the 10<sup>th</sup> percentile or above and less than the 90<sup>th</sup> percentile. Infants with birth weight greater than the 90<sup>th</sup> percentile were excluded to prevent the confounding impact of poor outcomes in LGA infants. We determined the overlap of this definition with SGA defined by Fenton criteria and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) consensus FGR definition. 10,28

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

Association of Genetic Disorders with SGA versus AGA birth among preterm infants We performed multiple variable logistic regression of the association of the following maternal and infant characteristics: ethnicity/race (maternal self-declared), maternal age, diagnosis of genetic disorders, the presence of congenital anomalies (defined as clinician diagnosed anomalies of the heart, gastrointestinal tract, brain, lungs, kidneys and urinary tract, or the presence of hydrops), and year of discharge. Congenital anomalies themselves are strongly associated with genetic disorders. Therefore, we tested for an interaction between congenital anomalies and genetic disorders with the outcome of SGA birth. This analysis was also repeated limiting the cohort to infants born following singleton gestation to test the effect of multiple gestation. Unadjusted odds of SGA versus AGA birth were determined for each genetic disorder in which SGA birth was observed. The prevalence rate of SGA birth across maternal age was also determined. Association of genetic disorders with morbidity and mortality within preterm SGA infants Next, we evaluated factors associated with severe morbidity or mortality within preterm SGA infants. To limit ascertainment bias, infants transferred after birth or prior to discharge were excluded from the analysis of clinical outcomes.<sup>29</sup> Multivariable logistic regression was performed for severe morbidity or mortality as a combined clinical outcome. Severe morbidity was defined as any of the following: acute kidney injury (AKI) defined by the diagnosis of oliguria or anuria (ICD-9 788.5 or ICD-10: R34); severe intracranial hemorrhage (ICH) defined as grade III or IV intraventricular hemorrhage by Papile criteria or cystic periventricular leukomalacia; <sup>30</sup> medically or surgically treated necrotizing enterocolitis (NEC); severe bronchopulmonary dysplasia (BPD) defined as invasive mechanical ventilation at 36 weeks' postmenstrual age; severe retinopathy of prematurity (ROP) defined as need for any medical or surgical intervention; culture-positive sepsis defined by any positive blood or urine culture; or

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

shock defined as administration of any vasopressor or inotrope. The following were covariates: exposure to antenatal betamethasone, mode of delivery (vaginal delivery was treated as reference), phenotypic sex (female was treated as reference given the associated risk of morbidity in male infants), 31,32 race (White race was treated as reference given thee proportional size), gestational age, birth weight Z-score, discharge year epoch (2000-2004, 2005-2009, 2010-2014, 2015-2020), intubation in the first 72 hours of life, presence of a known genetic disorder, and the presence of congenital anomalies. This analysis was repeated limiting the cohort to infants born following singleton gestation to test the effect of multiple gestations. As before, we also tested for an interaction between genetic disorders and congenital anomalies and the outcome of morbidity or mortality. Finally, we sought to evaluate how SGA preterm infants with or without congenital anomalies compared to AGA preterm infants with respect to rates of morbidity and mortality. Using AGA preterm infants as reference for both analyses, we determined the crude odds ratios (OR) of individual comorbidities for preterm infants born SGA without congenital anomalies and for preterm infants born SGA with congenital anomalies. Analyses were made using RStudio version 2022.07.0 (R Project for Statistical Computing) (eMethods in the **Supplement**).<sup>33</sup> Results 378 887 SGA and AGA infants were identified in this cohort (Table 1). Of these, 176 791 (46.7%) were female. The mean (SD) gestational age was 30.1 (2.86) weeks, and the mean (SD) birth weight was 1.44 (0.49) kg. Genetic disorders were diagnosed in 5 386 (1.4%) infants. Congenital anomalies were present in 24 463 (6.4%) of infants. 36 985 (9.8%) infants were defined as SGA. 36 985 infants met this definition, all of whom were below the 10<sup>th</sup> percentile for NICHD fetal growth (Supplemental Figure 1). 33 451 (92.1%) of these infants were also below the Fenton 10<sup>th</sup> percentile definition of SGA birth.

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Association of Genetic Disorders with SGA versus AGA birth among preterm infants Genetic disorders were present in 1112 (3.0%) of the 36 985 preterm SGA infants and in 4274 (1.3%) of the 341 902 preterm AGA infants in this cohort. Multivariable logistic regression demonstrated higher adjusted OR of SGA versus AGA birth for infants born to mothers identifying as Asian or Black (versus White) and lower for those born to mothers identifying as Hispanic (versus White) (Figure 1). Known genetic disorders and congenital anomalies (except for fetal hydrops and pulmonary anomalies) were also found to be associated with SGA birth in preterm infants. SGA birth was not found to vary across the period of this study (2000–2020). Nearly identical results were found for all covariates when this regression was limited to infants born following singleton gestation (Supplemental Figure 2). Greater maternal age was also associated with SGA birth (Figure 3). The association between genetic disorders and SGA birth was not driven by a single genetic disorder. Rather, SGA birth was associated with multiple known diagnoses including trisomy 13, trisomy 18, trisomy 21, Turner syndrome, unspecified aneuploidy, unspecified copy number variant, sickle cell anemia, cystic fibrosis, hypophosphatasia, and the presence of multiple genetic disorders (Supplemental Table 1). As a secondary analysis, we repeated this regression testing for an interaction between the presence of genetic disorders and the presence of any congenital anomaly. We found that these factors each independently associated with SGA versus AGA birth in preterm infants, but we did not find a significant interaction between these factors and SGA birth. Association of genetic disorders with morbidity and mortality within preterm SGA infants We next focused on morbidity and mortality within the subset of 36 985 SGA preterm infants. After excluding infants transferred in or to other facilities, and those with missing data, 28 983 SGA preterm infants remained (Figure 2). Genetic disorders were present in 375 (4.3%) of the 8810 preterm SGA infants that experienced severe morbidity or mortality as compared to 415

(2.1%) of the 20 173 preterm AGA infants that did not experience these outcomes. Antenatal betamethasone, birth in later years, maternal identification as Asian or Black (versus White), increased gestational age, and increased birth weight all were associated with lower adjusted odds of morbidity or mortality. Male sex, maternal identification as Hispanic (versus White), intubation in the first 72 hours of life, the presence of known genetic disorders, or congenital anomalies were associated with greater adjusted odds of morbidity or mortality. Nearly identical results were found for all covariates when this regression was limited to infants born following singleton gestation pregnancy (Supplemental Figure 3). Compared to AGA preterm infants, SGA preterm infants with or without other congenital anomalies experienced higher rates of death and every comorbidity, with the exception of severe ICH, which was observed to occur less frequently in infants with isolated SGA status compared to all AGA infants. (Table 2). As a secondary analysis, we repeated this regression with a test for an interaction between the presence of genetic disorders and the presence of any congenital anomaly. We found that SGA preterm infants with genetic disorders and congenital anomalies had an adjusted odds ratio (95% confidence interval) of 1.52 (1.03, 2.27) for severe morbidity or mortality.

## **Discussion**

The primary finding of our study was that genetic disorders were strongly and nonspecifically associated with preterm SGA birth, morbidity, and mortality. There are important strengths, limitations, and clinical implications of this finding. Our analysis revealed several secondary findings as well: lower birth weight and higher risk of illness in preterm infants with cystic fibrosis and hypophosphatasia, a synergistic risk of illness in infants with congenital anomalies and genetic disorders, and a lower rate of severe ICH in preterm SGA infants without congenital anomalies. In the following we discuss the primary and secondary findings of our research.

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Using a highly generalizable cohort, we found that commonly diagnosed genetic disorders were twice as prevalent in SGA infants compared to AGA infants, and that genetic disorders were strongly associated with SGA birth weight after adjusting for known risk factors. Genetic disorders were also strongly associated with severe morbidity and mortality in this population. We confirmed previously described associations between common aneuploidies and SGA birth, morbidity, and mortality. Interestingly, we found a broad association between genetic disorders and preterm SGA birth. Of the 20 genetic disorders analyzed (including "unspecified" cases of aneuploidy or copy number variants), significant associations with SGA birth were found in 10, and nonsignificant trends towards this association were found in 8. Cystic fibrosis has recently been implicated as a cause of lower birth weight and earlier gestation of birth.<sup>34</sup> which our data support. We also found evidence of a novel association between hypophosphatasia and preterm SGA birth, as well as significantly greater odds of morbidity or mortality. If confirmed, these findings might illuminate pathogenic mechanisms of growth restriction. Multiple gestations have typically been excluded in large cohort studies limiting the generalizability of findings. We found similar results with or without this exclusion. However, we did not evaluate pairwise outcomes within twin or greater multiple gestations. Clinicians and families, particularly in the setting of growth discordant twins, often must consider risks and benefits in timing of delivery. Targeted focus on SGA multiple gestations could help better inform these decisions, as well as validate twin-specific growth charts.<sup>35</sup> Unique factors in twin pregnancies including unequal placentation, twin-twin transfusion, and birth weight discordance all may influence clinical outcomes, and should be explored further. 36,37 In addition to genetic disorders, we found that congenital anomalies were strongly associated with preterm SGA birth, morbidity, and mortality. Congenital anomalies of the kidney, heart, brain, and other organ systems are themselves strongly linked to genetic disorders. It is unclear

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

if anomalies themselves caused lower birth weight and illness, or if anomalies were the sentinel features of underlying genetic disorders. A parsimonious explanation is that underlying genetic disorders contribute to congenital anomalies, poor fetal growth, and severe morbidity. This is further supported by the finding that genetic disorders and congenital anomalies interacted to confer synergistically greater risk of morbidity and mortality in SGA preterm infants. Intriguingly, preterm SGA infants without congenital anomalies were found to have lower odds of severe ICH compared to AGA infants. Fetal growth restriction and SGA birth have been described as protective against severe intraventricular hemorrhage in extremely preterm (born < 28 weeks' gestation) infants. 6,8,38-40 The implication of a lower risk of severe ICH in SGA birth without other anomalies warrants attention given reports of higher risk of neurodevelopmental impairment including poorer cognitive outcomes in this population.<sup>41</sup> Administration of antenatal corticosteroids reduces the risk of severe IVH and mortality, but studies have suggested that steroids in SGA preterm infants may not reduce serious morbidities. 42,43 Although a previous landmark trial reported a potential reduction in severe IVH but no effect on neurosensory impairment with the use of prophylactic indomethacin in extremely low birth weight infants, multiple studies have refuted this finding. 44-46 Replication, functional validation, and basic investigation into protection of IVH in growth restricted extremely preterm infants may inform novel therapies. Our study had several compelling strengths. This represents the largest and most comprehensive examination of factors associated with preterm SGA status and comorbidities to our knowledge. This was a multicenter investigation of infants from diverse backgrounds, with generalizable results. There are important limitations to this study. Infants born SGA may be more likely to undergo pre- or postnatal genetic testing, especially in the presence of other congenital anomalies or comorbidities. Details regarding testing, including time (pre- or

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

postnatal) and indication are unknown in this cohort. Genetic testing has also undergone dramatic changes from 2000 to 2020. There is likely substantial heterogeneity in the genetic workups performed across this period. Unfortunately, data are not available regarding the spectrum of testing performed in the cohort, including negative results. There may also be heterogeneity in the assignment of gestational age. The method used to determine this for each individual in the cohort is unknown. Additionally, SGA and FGR are defined differently in the literature of this field. We defined SGA birth here using the distribution of birth weight found within this cohort. This definition increases the internal validity or our analysis but may limit generalization. Given that our definition of SGA shared 92.1% with Fenton-defined SGA infants, this is unlikely. The optimal criteria for defining a newborn as SGA or growth restricted likely include individual environmental, genetic, and biological factors, many of which are yet unknown. These analyses also did not consider when growth restriction occurred during pregnancy, patterns of growth restriction (such as head-sparing or symmetric), fetal exposures, postnatal growth patterns, or social determinants of health. Our dataset lacks maternal records, including the presence of comorbidities that may contribute to placental insufficiency. Our finding that extremes of maternal age, as well as increasing maternal age from 18 to 34 years, were associated with SGA status likely reflects the contribution of these maternal factors. Genetic counseling and consideration of testing for FGR is recommended by the American College of Obstetricians and Gynecologists as well as by the Society for Maternal and Fetal Medicine. 47,48 There is not yet consensus regarding the postnatal evaluation of SGA infants. 49,50 Scarce data exist regarding how often genetic workups or testing are actually performed pre- or postnatally for these indications. Furthermore, perinatal genetic disorders often present nonspecifically and are often diagnosed belatedly. 51,52 The indications and potential benefit for genetic testing in this population is unknown without prospective, genome-wide testing.

Our findings have implications for clinical practice and further research. Clinicians should strongly consider genetic testing of preterm SGA infants, particularly in the setting of other comorbidities or anomalies. Genetic disorders were found in 3.0% of preterm SGA infants overall and 4.3% of preterm SGA infants with severe morbidity and mortality. These represent underestimates as prospective testing was not preformed. Without prospective genetic testing the baseline rate genetic disorders in this population is unknown. Preterm SGA infants with genetic disorders or congenital anomalies may be at higher risk for morbidity and mortality. Clinicians should consider this risk when counseling families, evaluating the risks and benefits of management decisions, or estimating the pre-test probability of diagnostic tests. Prospective genomic research is urgently needed to clarify the contribution of genetic disorders to disease in this population.

Acknowledgements

The authors wish to gratefully acknowledge Dr. Ali G. Gharavi (Columbia University Irving Medical Center) and his research team, as well as Dr. Joseph M. Feinglass (Feinberg School of Medicine, Northwestern University) for their mentorship and thoughtful review of this project.

Authors TH and JEM are supported by *Thrasher Research Fund Early Career Awards*. TH is also supported by the *NIH National Center for Advancing Translational Sciences* (KL2TR001874).

Supplemental Materials

Supplemental Table 1. Unadjusted odds of SGA birth within diagnosed genetic disorders.

Supplemental Figure 1. Classification of SGA or FGR birth in this cohort by related criteria.

Supplemental Figure 2. Multivariable logistic regression for SGA versus AGA status in preterm infants with singleton gestation.

Supplemental Figure 3. Multivariable logistic regression for severe morbidity or mortality in SGA preterm infants following singleton gestation.

eMethods. R studio script used for this project.

Table 1. Descriptive characteristics of cohort

319

Characteristic	AGA (N=341902)	SGA (N=36985)	P-value
Sex	•	-	-
Female	159615 (46.7%)	17176 (46.4%)	0.375
Male	182287 (53.3%)	19809 (53.6%)	
Gestational Age (weeks)			
Mean (SD)	30.1 (2.88)	30.2 (2.69)	<0.001
Median [Min, Max]	31.0 [23.0, 33.0]	31.0 [23.0, 33.0]	
Race and Ethnicity			
Asian	9698 (2.8%)	1152 (3.1%)	<0.001
Black	79022 (23.1%)	10128 (27.4%)	
Hispanic	66839 (19.5%)	6157 (16.6%)	
Other	25385 (7.4%)	2851 (7.7%)	
White	160958 (47.1%)	16697 (45.1%)	
Maternal Age			
Mean (SD)	28.1 (6.52)	28.5 (6.57)	<0.001
Median [Min, Max]	28.0 [10.0, 60.0]	28.0 [10.0, 58.0]	
Missing	1494 (0.4%)	126 (0.3%)	
Discharge Year			
2000 to 2004	56242 (16.4%)	5979 (16.2%)	0.025
2005 to 2009	90974 (26.6%)	9809 (26.5%)	
2010 to 2014	91931 (26.9%)	9810 (26.5%)	
2015 to 2020	102755 (30.1%)	11387 (30.8%)	
Genetic Disorder			
Absent	337628 (98.8%)	35873 (97.0%)	<0.001
Present	4274 (1.3%)	1112 (3.0%)	
Congenital Anomaly			
Absent	321063 (93.9%)	33361 (90.2%)	<0.001
Kidney or urinary tract	5082 (1.5%)	834 (2.3%)	
Heart	5555 (1.6%)	925 (2.5%)	
Central nervous system	3718 (1.1%)	611 (1.7%)	
Gastrointestinal tract	3674 (1.1%)	649 (1.8%)	
Hydrops	321 (0.1%)	36 (0.1%)	
Multiple organ systems	2066 (0.6%)	513 (1.4%)	
Pulmonary	423 (0.1%)	56 (0.2%)	

Abbreviations: AGA (appropriate for gestational age), SGA (small for gestational age)

Table 2. Unadjusted odds of mortality or severe morbidities in preterm SGA infants.

	OR (99.44% CI)				
Outcome	Preterm SGA Infants without Congenital Anomalies (versus AGA Preterm Infants)	Preterm SGA Infants with Additional Congenital Anomalies (versus AGA Preterm Infants)			
Mortality or any morbidity	1.45 (1.39, 1.50)	4.86 (4.33, 5.46)			
Mortality	1.99 (1.87, 2.12)	5.96 (5.20, 6.83)			
Acute kidney injury	1.60 (1.46, 1.75)	5.03 (4.22, 6.00)			
Severe intracranial hemorrhage	0.82 (0.75, 0.91)	1.89 (1.52, 2.36)			
Severe necrotizing enterocolitis	1.28 (1.18, 1.40)	3.50 (2.91, 4.21)			
Severe bronchopulmonary dysplasia	2.40 (2.13, 2.70)	9.50 (7.78, 11.59)			
Severe retinopathy of prematurity	1.52 (1.33, 1.74)	3.14 (2.31, 4.27)			
Sepsis	1.37 (1.29, 1.45)	3.22 (2.81, 3.68)			
Shock	1.35 (1.28, 1.43)	3.18 (2.78, 3.64)			


Abbreviations: CI (confidence interval), OR (odds ratio), SGA (small for gestational age)

Variable		N	Odds ratio		р
Race and Ethnicity	White	177138	•	Reference	
	Asian	10811	=	1.10 (1.04, 1.18)	0.002
	Black	88877		1.24 (1.21, 1.28)	<0.001
	Hispanic	72747	<b>■</b> ;	0.89 (0.86, 0.92)	<0.001
	Other	27694		1.07 (1.03, 1.12)	0.001
Maternal Age (years)	10-19	36857	•	Reference	
	20-29	182044	=	1.12 (1.08, 1.16)	< 0.001
	30-39	142563	. ■	1.19 (1.15, 1.24)	<0.001
	40-49	15600		1.33 (1.25, 1.42)	<0.001
	50-60	203		1.54 (0.98, 2.29)	0.046
Discharge Year	2000 to 2004	62190		Reference	
	2005 to 2009	100052	<b></b>	1.01 (0.97, 1.04)	0.717
	2010 to 2014	101153		0.98 (0.95, 1.02)	0.329
	2015 to 2020	113872	•	1.00 (0.97, 1.04)	0.939
Genetic Disorder	Absent	371906	•	Reference	
	Present	5361	•	2.06 (1.92, 2.21)	<0.001
Congenital Anomaly	Absent	352898	•	Reference	
	Cardiac	6458		1.51 (1.41, 1.62)	< 0.001
	Gastrointestinal	4304	-	1.68 (1.55, 1.83)	< 0.001
	Hydrops	356	-	1.03 (0.72, 1.43)	0.869
	Multiple	2568	-	2.18 (1.97, 2.40)	< 0.001
	Neurological	4311	-	1.54 (1.41, 1.68)	<0.001
	Pulmonary	476	<u>-</u>	1.28 (0.96, 1.68)	0.081
	Renal	5896	-	1.58 (1.47, 1.70)	<0.001

**Figure 1:** Multivariable regression of clinical characteristics of preterm infants born SGA versus AGA. Regression was performed for the outcome of SGA birth within infants born before 34 weeks' gestation. Maternal identification as Hispanic was associated with lower adjusted odds of SGA status. Maternal identification as Asian or Black, advancing maternal age, the presence of a known genetic disorder, and the presence of congenital anomalies (excluding hydrops and pulmonary anomalies) were associated with greater adjusted odds of SGA status.

Variable		N	Odds ratio		р
Antenatal Betamethasone	No	4688		Reference	
	Yes	24295		0.70 (0.64, 0.77)	< 0.001
Sex	Female	13584		Reference	
	Male	15399		1.17 (1.10, 1.25)	< 0.001
Race and Ethnicity	White	13117		Reference	
	Asian	929		0.80 (0.65, 0.98)	0.034
	Black	7955		0.88 (0.81, 0.95)	0.001
	Hispanic	4792		1.31 (1.19, 1.44)	< 0.001
	Other	2190		0.93 (0.82, 1.07)	0.320
Gestational Age (weeks)		28983		0.61 (0.60, 0.62)	< 0.001
Birth Weight (Z-score)		28983		0.40 (0.37, 0.43)	< 0.001
Delivery Mode	Vaginal	2565		Reference	
	Cesarean Section	26418		0.64 (0.57, 0.73)	< 0.001
Discharge Year	2000 to 2004	4423		Reference	
•	2005 to 2009	7773		0.98 (0.89, 1.09)	0.734
	2010 to 2014	7883		0.70 (0.63, 0.78)	< 0.001
	2015 to 2020	8904		0.62 (0.56, 0.69)	< 0.001
Intubation within 72 Hours	No	17689		Reference	
	Yes	11294	i <b>.</b>	2.86 (2.66, 3.08)	< 0.001
Genetic Disorder	Absent	28193		Reference	
	Present	790	<b>:</b> ■	2.12 (1.77, 2.55)	< 0.001
Congenital Anomaly	Absent	26645		Reference	
	Cardiac	568	¦∎	2.07 (1.68, 2.56)	< 0.001
	Gastrointestinal	373	! ■	5.11 (3.91, 6.71)	< 0.001
	Hydrops	24	i —	17.38 (4.93, 85.73)	< 0.001
	Multiple	295		8.91 (6.65, 12.01)	< 0.001
	Neurological	406	· •	3.36 (2.62, 4.30)	< 0.001
	Pulmonary	41	-	4.69 (2.23, 10.27)	< 0.001
	Renal	631	: <b>-</b>	2.29 (1.87, 2.81)	< 0.001

Figure 2. Multivariable logistic regression of clinical characteristics of preterm SGA infants with severe morbidity or mortality (versus preterm SGA infants without severe morbidity or mortality). Within the subset of preterm infants born SGA, regression was performed against the combined outcome of mortality or severe morbidity. Antenatal betamethasone, maternal identification as Asian or Black, increasing gestational age, increasing birth weight, cesarean delivery, and later epochs were found to be associated with lower adjusted odds of the composite outcome. Male sex, maternal identification as Hispanic, intubation after birth, and the presence of known genetic disorders or congenital anomalies were associated with greater adjusted odds of the composite outcome.



**Figure 3.** Prevalence of SGA birth by maternal age. The prevalence of SGA birth was determined (within preterm births) for each year of maternal age from 15 to 50. Error bars depict the 95% CI. Extreme maternal ages, less than 15 and greater than 50, were excluded from the analysis due to their small sample size. For each one year increase in maternal age, on average, there was a 0.107 increase in SGA prevalence per 100 preterm births (adjusted  $r^2 = 0.46$ , p = <0.001).

## References

- 1. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality
- among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford
- 361 Network. Am J Obstet Gynecol. Jan 2000;182(1 Pt 1):198-206. doi:10.1016/s0002-
- 362 9378(00)70513-8
- 363 2. Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality
- and morbidity in a very preterm birth cohort. J Pediatr. Nov 2010;157(5):733-9.e1.
- 365 doi:10.1016/j.jpeds.2010.05.002
- 366 3. Peacock JL, Lo JW, D'Costa W, Calvert S, Marlow N, Greenough A. Respiratory
- morbidity at follow-up of small-for-gestational-age infants born very prematurely. *Pediatr Res.*
- 368 Apr 2013;73(4 Pt 1):457-63. doi:10.1038/pr.2012.201
- 369 4. De Jesus LC, Pappas A, Shankaran S, et al. Outcomes of small for gestational age
- infants born at <27 weeks' gestation. *J Pediatr*. Jul 2013;163(1):55-60.e1-3.
- 371 doi:10.1016/j.jpeds.2012.12.097
- 372 5. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and
- 373 mortality among premature neonates. *Am J Obstet Gynecol*. Aug 2004;191(2):481-7.
- 374 doi:10.1016/j.ajog.2004.01.036
- 375 6. Mendez-Figueroa H, Truong VT, Pedroza C, Chauhan SP. Morbidity and Mortality in
- 376 Small-for-Gestational-Age Infants: A Secondary Analysis of Nine MFMU Network Studies. Am J
- 377 *Perinatol.* Mar 2017;34(4):323-332. doi:10.1055/s-0036-1586502
- 378 7. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among
- infants 501 to 1500 grams from 2000 to 2009. *Pediatrics*. Jun 2012;129(6):1019-26.
- 380 doi:10.1542/peds.2011-3028
- 8. Baer RJ, Rogers EE, Partridge JC, et al. Population-based risks of mortality and preterm
- morbidity by gestational age and birth weight. *J Perinatol*. Nov 2016;36(11):1008-1013.
- 383 doi:10.1038/jp.2016.118
- 384 9. Minor KC, Bianco K, Sie L, Druzin ML, Lee HC, Leonard SA. Severity of small-for-
- gestational-age and morbidity and mortality among very preterm neonates. *J Perinatol*. Apr
- 386 2023;43(4):437-444. doi:10.1038/s41372-022-01544-w
- 387 10. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth
- 388 chart for preterm infants. BMC Pediatr. Apr 20 2013;13:59. doi:10.1186/1471-2431-13-59
- 389 11. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A.
- 390 Management of the child born small for gestational age through to adulthood: a consensus
- 391 statement of the International Societies of Pediatric Endocrinology and the Growth Hormone
- 392 Research Society. J Clin Endocrinol Metab. Mar 2007;92(3):804-10. doi:10.1210/jc.2006-2017
- 393 12. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for
- 394 Gestational Age Advisory Board consensus development conference statement: management
- of short children born small for gestational age, April 24-October 1, 2001. *Pediatrics*. Jun
- 396 2003;111(6 Pt 1):1253-61. doi:10.1542/peds.111.6.1253
- 397 13. Katz J, Lee AC, Kozuki N, et al. Mortality risk in preterm and small-for-gestational-age
- infants in low-income and middle-income countries: a pooled country analysis. *Lancet*. Aug 3
- 399 2013;382(9890):417-425. doi:10.1016/s0140-6736(13)60993-9
- 400 14. Finken MJJ, van der Steen M, Smeets CCJ, et al. Children Born Small for Gestational
- 401 Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. *Endocr Rev.* Dec 1
- 402 2018;39(6):851-894. doi:10.1210/er.2018-00083
- 403 15. McCowan L, Horgan RP. Risk factors for small for gestational age infants. Best Pract
- 404 Res Clin Obstet Gynaecol. Dec 2009;23(6):779-93. doi:10.1016/j.bpobgyn.2009.06.003
- 405 16. Wollmann HA. Intrauterine growth restriction: definition and etiology. *Horm Res.* 1998;49
- 406 Suppl 2:1-6. doi:10.1159/000053079

- 407 17. Mone F, Mellis R, Gabriel H, et al. Should we offer prenatal exome sequencing for
- intrauterine growth restriction or short long bones? A systematic review and meta-analysis. *Am*
- 409 J Obstet Gynecol. Oct 7 2022;doi:10.1016/j.ajog.2022.09.045
- 410 18. Meler E, Sisterna S, Borrell A. Genetic syndromes associated with isolated fetal growth
- 411 restriction. *Prenat Diagn*. Mar 2020;40(4):432-446. doi:10.1002/pd.5635
- 412 19. Peng R, Yang J, Xie HN, Lin MF, Zheng J. Chromosomal and subchromosomal
- 413 anomalies associated to small for gestational age fetuses with no additional structural
- 414 anomalies. *Prenat Diagn*. Dec 2017;37(12):1219-1224. doi:10.1002/pd.5169
- 415 20. Borrell A, Grande M, Meler E, et al. Genomic Microarray in Fetuses with Early Growth
- 416 Restriction: A Multicenter Study. Fetal Diagn Ther. 2017;42(3):174-180. doi:10.1159/000452217
- 417 21. Motelow JE, Lippa NC, Hostyk J, et al. Risk Variants in the Exomes of Children With
- 418 Critical Illness. *JAMA Netw Open*. Oct 3 2022;5(10):e2239122.
- 419 doi:10.1001/jamanetworkopen.2022.39122
- 420 22. Stanley KE, Giordano J, Thorsten V, et al. Causal Genetic Variants in Stillbirth. N Engl J
- 421 *Med.* Sep 17 2020;383(12):1107-1116. doi:10.1056/NEJMoa1908753
- 422 23. Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation
- of fetal structural anomalies: a prospective cohort study. Lancet. Feb 23 2019;393(10173):758-
- 424 767. doi:10.1016/S0140-6736(18)32042-7
- 425 24. Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal
- 426 structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet*. Feb 23
- 427 2019;393(10173):747-757. doi:10.1016/S0140-6736(18)31940-8
- 428 25. Bertoli-Avella AM, Beetz C, Ameziane N, et al. Successful application of genome
- sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort.
- 430 Eur J Hum Genet. Jan 2021;29(1):141-153. doi:10.1038/s41431-020-00713-9
- 431 26. Hays T, Wapner RJ. Genetic testing for unexplained perinatal disorders. *Curr Opin*
- 432 *Pediatr*. Apr 1 2021;33(2):195-202. doi:10.1097/MOP.0000000000000999
- 433 27. Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data
- Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful
- use" in continuous quality improvement. Clin Perinatol. Mar 2010;37(1):49-70.
- 436 doi:10.1016/j.clp.2010.01.016
- 437 28. Grantz KL, Grewal J, Kim S, et al. Unified standard for fetal growth: the Eunice Kennedy
- 438 Shriver National Institute of Child Health and Human Development Fetal Growth Studies. Am J
- 439 Obstet Gynecol. Apr 2022;226(4):576-587.e2. doi:10.1016/j.ajog.2021.12.006
- 440 29. Tolia VN, Clark RH. The Denominator Matters! Lessons from Large Database Research
- 441 in Neonatology. Children (Basel). Nov 7 2020;7(11):216-216. doi:10.3390/children7110216
- 442 30. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal
- and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J
- 444 Pediatr. Apr 1978;92(4):529-34. doi:10.1016/s0022-3476(78)80282-0
- 445 31. Stevenson DK, Verter J, Fanaroff AA, et al. Sex differences in outcomes of very low
- birthweight infants: the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed. Nov
- 447 2000;83(3):F182-5. doi:10.1136/fn.83.3.f182
- 448 32. Peacock JL, Marston L, Marlow N, Calvert SA, Greenough A. Neonatal and infant
- outcome in boys and girls born very prematurely. *Pediatr Res.* Mar 2012;71(3):305-10.
- 450 doi:10.1038/pr.2011.50
- 451 33. R: A language and environment for statistical computing. R Foundation for Statistical
- 452 Computing; 2022. <a href="https://www.R-project.org/">https://www.R-project.org/</a>
- 453 34. Schlüter DK, Griffiths R, Adam A, et al. Impact of cystic fibrosis on birthweight: a
- 454 population based study of children in Denmark and Wales. *Thorax*. 2019;74(5):447-454.
- 455 doi:10.1136/thoraxjnl-2018-211706

- 456 35. Giorgione V, Briffa C, Di Fabrizio C, Bhate R, Khalil A. Perinatal Outcomes of Small for
- 457 Gestational Age in Twin Pregnancies: Twin vs. Singleton Charts. *J Clin Med*. Feb 8
- 458 2021;10(4)doi:10.3390/jcm10040643
- 459 36. D'Antonio F, Khalil A, Dias T, Thilaganathan B. Weight discordance and perinatal
- 460 mortality in twins: analysis of the Southwest Thames Obstetric Research Collaborative (STORK)
- 461 multiple pregnancy cohort. *Ultrasound Obstet Gynecol*. Jun 2013;41(6):643-8.
- 462 doi:10.1002/uog.12412
- 463 37. Townsend R, Khalil A. Fetal growth restriction in twins. Best Pract Res Clin Obstet
- 464 *Gynaecol*. May 2018;49:79-88. doi:10.1016/j.bpobgyn.2018.02.004
- 465 38. Kim F, Bateman DA, Goldshtrom N, Sheen J-J, Garey D. Intracranial ultrasound
- 466 abnormalities and mortality in preterm infants with and without fetal growth restriction stratified
- by fetal Doppler study results. *Journal of Perinatology*. 2023/01/30 2023;doi:10.1038/s41372-
- 468 023-01621-8
- 469 39. Procianoy RS, Garcia-Prats JA, Adams JM, Silvers A, Rudolph AJ. Hyaline membrane
- disease and intraventricular haemorrhage in small for gestational age infants. Arch Dis Child.
- 471 Jul 1980;55(7):502-5. doi:10.1136/adc.55.7.502
- 472 40. Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth
- 473 restriction. American Journal of Obstetrics and Gynecology. 2003/06/01/ 2003;188(6):1596-
- 474 1601. doi:https://doi.org/10.1067/mob.2003.384
- 475 41. Sacchi C, Marino C, Nosarti C, Vieno A, Visentin S, Simonelli A. Association of
- 476 Intrauterine Growth Restriction and Small for Gestational Age Status With Childhood Cognitive
- Outcomes: A Systematic Review and Meta-analysis. JAMA Pediatr. Aug 1 2020;174(8):772-
- 478 781. doi:10.1001/jamapediatrics.2020.1097
- 479 42. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating
- fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. Mar 21
- 481 2017;3(3):Cd004454. doi:10.1002/14651858.CD004454.pub3
- 482 43. Blankenship SA, Brown KE, Simon LE, Stout MJ, Tuuli MG. Antenatal corticosteroids in
- 483 preterm small-for-gestational age infants: a systematic review and meta-analysis. Am J Obstet
- 484 *Gynecol MFM.* Nov 2020;2(4):100215. doi:10.1016/j.ajogmf.2020.100215
- 485 44. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis
- in extremely-low-birth-weight infants. *N Engl J Med*. Jun 28 2001;344(26):1966-72.
- 487 doi:10.1056/nejm200106283442602
- 488 45. Mirza H, Laptook AR, Oh W, et al. Effects of indomethacin prophylaxis timing on
- 489 intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants.
- 490 Arch Dis Child Fetal Neonatal Ed. Sep 2016;101(5):F418-22. doi:10.1136/archdischild-2015-
- 491 309112
- 492 46. Foglia EE, Roberts RS, Stoller JZ, Davis PG, Haslam R, Schmidt B. Effect of
- 493 Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk
- 494 of Severe Intraventricular Hemorrhage. *Neonatology*. 2018;113(2):183-186.
- 495 doi:10.1159/000485172
- 496 47. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet Gynecol. Feb 1
- 497 2021;137(2):e16-e28. doi:10.1097/aog.0000000000004251
- 498 48. Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series
- 499 #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline
- 500 Number 3, April 2012). Am J Obstet Gynecol. Oct 2020;223(4):B2-b17.
- 501 doi:10.1016/j.ajog.2020.05.010
- 502 49. Dauber A. Genetic Testing for the Child With Short Stature-Has the Time Come To
- 503 Change Our Diagnostic Paradigm? J Clin Endocrinol Metab. Jul 1 2019;104(7):2766-2769.
- 504 doi:10.1210/jc.2019-00019
- 505 50. Rapaport R, Wit JM, Savage MO. Growth failure: 'idiopathic' only after a detailed
- 506 diagnostic evaluation. *Endocr Connect*. Mar 2021;10(3):R125-r138. doi:10.1530/ec-20-0585

51. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. *NPJ Genom Med.* 2018;3(1):16. doi:10.1038/s41525-018-0053-8
52. Wojcik MH, Schwartz TS, Yamin I, et al. Genetic disorders and mortality in infancy and early childhood: delayed diagnoses and missed opportunities. *Genet Med.* Nov 2018;20(11):1396-1404. doi:10.1038/gim.2018.17


Supplemental Table 1. Unadjusted odds of SGA birth associated for specific genetic disorders.

Genetic Disorder	SGA (n)	AGA (n)	OR (99.75% CI)
Aneuploidy			
Trisomy 13	32	109	2.76 (1.50–5.08)
Trisomy 18	145	80	17.06 (11.19-26.00)
Trisomy 21	286	987	2.73 (2.22-3.34)
Trisomy 22	1	2	4.71 (0.12-190.89)
Turner syndrome	17	34	4.71 (1.92-11.55)
Klinefelter syndrome	9	35	2.42 (0.78-7.49)
Unspecified aneuploidy	204	554	3.47 (2.70-4.44)
Copy Number Variant			
13q deletion	3	8	3.53 (0.46-27.33)
Cri-du-chat	4	17	2.21 (0.41-11.88)
DiGeorge syndrome	9	54	1.57 (0.53-4.66)
Unspecified copy number variant	15	31	4.55 (1.76-11.79)
Hematologic Single Gene Disorder			
Hemophilia A	1	12	0.78 (0.03-18.25)
Thalassemia	169	1256	1.27 (0.99-1.62)
Hemoglobin Bart's	39	391	0.94 (0.56-1.56)
Sickle cell anemia	48	196	2.30 (1.42-3.75)
G6PD deficiency	32	200	1.51 (0.85-2.68)

Genetic Disorder	SGA (n)	AGA (n)	OR (99.75% CI)
Fanconi anemia	2	1	18.82 (0.46-763.54)
Miscellaneous			
Cystic fibrosis	48	206	2.19 (1.35-3.56)
Hypophosphatasia	41	80	4.82 (2.70-8.62)
Multiple diagnoses	7	9	7.32 (1.60-33.59)

Abbreviations: AGA (appropriate for gestational age), CI (confidence interval), OR (odds ratio), SGA (small for gestational age)

516



**Supplemental Figure 1.** Classification of SGA or FGR birth in this cohort by related criteria. This cohort included 409,399 preterm infants from the Pediatrix CDW. SGA was defined for this study as below the 10<sup>th</sup> percentile for gestational age and sex within the CDW cohort. 36,985 infants met this definition, all of whom were below the 10<sup>th</sup> percentile for NICHD fetal growth. 33,451 (92.1%) of these infants also fell below the Fenton 10<sup>th</sup> percentile definition of SGA birth. The numbers of infants meeting these criteria are depicted in the Euler diagram above.

Variable		N	Odds ratio		р
Race and Ethnicity	White	111314	•	Reference	
	Asian	7672	•	1.02 (0.94, 1.10)	0.7
	Black	67874	<b>—</b>	1.18 (1.14, 1.22)	< 0.001
	Hispanic	55644		0.82 (0.79, 0.85)	< 0.001
	Other	19812	•	1.03 (0.98, 1.08)	0.3
Maternal Age (years)	10-19	29599		Reference	
	20-29	129969		1.17 (1.12, 1.22)	< 0.001
	30-39	92726		1.26 (1.21, 1.32)	< 0.001
	40-49	9971		1.39 (1.29, 1.50)	< 0.001
	50-60	51		1.16 (0.40, 2.65)	8.0
Discharge Year	2000 to 2004	36019		Reference	
	2005 to 2009	71117		1.02 (0.97, 1.06)	0.5
	2010 to 2014	72055		1.01 (0.97, 1.05)	0.7
	2015 to 2020	83125		1.02 (0.98, 1.07)	0.3
Genetic Disorder	Absent	258130		Reference	
	Present	4186	; ■	2.09 (1.93, 2.25)	< 0.001
Congenital Anomaly	Absent	243621		Reference	
	Cardiac	4665	¦ <b>■</b>	1.40 (1.28, 1.52)	< 0.001
	Gastrointestinal	3506	; ■	1.52 (1.38, 1.67)	< 0.001
	Hydrops	279	<b></b> ■-	1.06 (0.71, 1.52)	8.0
	Multiple	2051		1.94 (1.73, 2.17)	< 0.001
	Neurological	3455	¦ <b>■</b>	1.38 (1.25, 1.53)	< 0.001
	Pulmonary	360	÷ <b>≡</b> →	1.29 (0.93, 1.75)	0.1
	Renal	4379		1.56 (1.43, 1.69)	<0.001
			0.5 1 1.5 22.5		

**Supplemental Figure 2.** Multivariable logistic regression for SGA versus AGA status in preterm infants with singleton gestation. The outcome of preterm SGA status was modeled as before (**Figure 1**) in only infants born following singleton gestation. Nearly identical adjusted odds were found for all covariates.

Variable		N	Odds ratio		р
Antenatal Betamethasone	No	3537		Reference	
	Yes	17542		0.66 (0.60, 0.73)	< 0.001
Sex	Female	9753		Reference	
	Male	11326		1.17 (1.08, 1.26)	< 0.001
Race and Ethnicity	White	8780		Reference	
	Asian	655		0.76 (0.59, 0.96)	0.03
	Black	6290		0.92 (0.84, 1.01)	0.09
	Hispanic	3712		1.44 (1.29, 1.60)	< 0.001
	Other	1642		0.99 (0.85, 1.15)	0.86
Gestational Age (weeks)		21079		0.61 (0.60, 0.62)	< 0.001
Birth Weight (Z-score)		21079	<b> </b>	0.38 (0.35, 0.42)	< 0.001
Delivery Mode	Vaginal	1948		Reference	
	Cesarean Section	19131		0.60 (0.52, 0.70)	< 0.001
Discharge Year	2000 to 2004	2651		Reference	
	2005 to 2009	5683		1.01 (0.89, 1.14)	0.93
	2010 to 2014	5893		0.72 (0.64, 0.82)	< 0.001
	2015 to 2020	6852		0.66 (0.58, 0.75)	< 0.001
Intubation within 72 Hours	No	12387		Reference	
	Yes	8692	i <b>-</b>	2.85 (2.61, 3.10)	< 0.001
Genetic Disorder	Absent	20445		Reference	
	Present	634	¦ <b>■</b>	2.17 (1.77, 2.66)	< 0.001
Congenital Anomaly	Absent	19301		Reference	
	Cardiac	411	¦ <b>■</b>	2.10 (1.63, 2.69)	< 0.001
	Gastrointestinal	292		5.67 (4.17, 7.74)	< 0.001
	Hydrops	19	; <b>——</b>	14.69 (3.93, 75.11)	< 0.001
	Multiple	222		8.91 (6.37, 12.57)	< 0.001
	Neurological	316		3.07 (2.32, 4.06)	< 0.001
	Pulmonary	30	-	7.61 (3.07, 20.95)	< 0.001
	Renal	488	: <b>-</b>	1.98 (1.57, 2.50)	< 0.001

**Supplemental Figure 3.** Multivariable logistic regression for severe morbidity or mortality in SGA preterm infants following singleton gestation. The combined outcome of mortality or severe morbidity status for preterm SGA infants was modeled as before (**Figure 2**) in only infants born following singleton gestation. Nearly identical adjusted odds were found for all covariates.

```
557
       eMethods
558
559
       The following script was used to generate tables and figures. The script was created using RStudio
560
       (version 2022.07.0).
561
562
       #### Table 1
563
564
       ## Import Data
565
566
        setwd("/Users/Miles/Desktop")
567
        Prevalence <- read.csv("Prev_Update_GxDx.csv")
568
        Prevalence1 <- Prevalence
569
        library(dplyr)
570
        library(table1)
571
572
       ## Data cleaning
573
574
       Prevalence2 <- Prevalence1 %>% filter(BW Z Score <= 1.282)
575
576
       Prevalence3 <- Prevalence2 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ 'SGA',
577
       BW Z Score \geq= -1.282 \sim 'AGA'))
578
579
       Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
580
581
       Prevalence4$DY <- as.factor(ifelse(Prevalence4$DischargeYear < 2005, "2000 to 2004",
582
       ifelse(Prevalence4$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4$DischargeYear < 2015,
       "2010 to 2014", "2015 to 2020"))))
583
584
585
       ## Label Data
586
587
       label(Prevalence4$BW) <- "Birthweight (kg)"
588
       label(Prevalence4$GA) <- "Gestational Age (weeks)"
589
       label(Prevalence4$GxDx) <- "Known Genetic Disorder"
590
       label(Prevalence4$Any Anom) <- "Congenital Anomaly"
591
       label(Prevalence4$SGA) <- "SGA Birth"
592
       label(Prevalence4$Genetic) <- "Genetic Disorder"
593
594
       ## Calculate p-values for Table1
595
596
       pvalue <- function(x, ...) {
597
         # Construct vectors of data y, and groups (strata) g
598
         y \leftarrow unlist(x)
599
         g <- factor(rep(1:length(x), times=sapply(x, length)))
600
         if (is.numeric(y)) {
601
          # For numeric variables, perform a standard 2-sample t-test
602
          p <- t.test(y \sim g) p.value
603
604
          # For categorical variables, perform a chi-squared test of independence
605
          p <- chisq.test(table(y, g))$p.value
606
607
         # Format the p-value, using an HTML entity for the less-than sign.
608
         # The initial empty string places the output on the line below the variable label.
609
         c("", sub("<", "&lt;", format.pval(p, digits=3, eps = 1e-200)))
610
611
612
       ## Table 1
```

```
613
       table1(~ Sex + GA + Race + MaternalAge + DY + Genetic + Any Anom |SGA, data=Prevalence4.
614
615
       overall=F, extra.col=list(`P-value`=pvalue))
616
617
       ####Table 2:
618
619
       ##Inport Data
620
621
       setwd("/Users/Miles/Desktop")
622
       Outcome <- read.csv("Outcome_Update_GxDx.csv")
623
       Outcome1 <- Outcome
624
       library(dplyr)
625
626
       ## Clean the data and make new varriables
627
       Outcome2 <- Outcome1 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ '1', BW_Z Score >= -
628
629
       1.282 \sim '0'))
630
631
       Outcome3 <- Outcome2 %>% filter(BW Z Score <= 1.282)
632
633
       Outcome4 <- Outcome3 %>% mutate(Additional Anom = ifelse(Any Anom == "Absent", "0", "1"))
634
635
       ##Perfom sum calculations
636
       sum(Outcome4$SGA == "1" & Outcome4$Additional Anom == "1" & Outcome4$CritIllorDeath == "Y")
637
       ##Used this model for all the possible scenarios and then put them into an excel sheet
638
       ##Excel Table 2 and Figure 2 were created for export
639
640
       ## Load packages
641
642
       library(tidyverse)
643
       library(pixiedust)
644
       library(kableExtra)
645
       library(webshot)
646
647
       ##Load data
648
649
       Pos <-read.csv("Figure 2 Bonferroni Corrected.csv")
650
651
       tbl1 <- dust(Pos)
652
653
       ##Plot
654
       tbl1 %>%
655
656
        sprinkle colnames(Outcome = "Outcome*", Isolated = "Isolated SGA", Syndromic= "SGA with Additional
657
       Congenital Anomaly") %>%
658
        kable() %>% kable_styling() %>%
659
        add header above(c(" " = 1, "OR (95% CI)" = 2))%>%
660
        kable classic(full width = F, html font = "Arial") %>%
661
        footnote("AKI: acute kidney injury, ICH: intracranial hemorrhage, NEC: necrotizing enterocolitis, BPD:
662
       bronchopulmonary dysplasia, ROP: retinopathy of prematurity", general title = "*Abbreviations")
663
664
       ####Figure 1
665
666
       ##import data
```

```
667
668
       setwd("/Users/Miles/Desktop")
669
        Prevalence <- read.csv("Prev Update GxDx.csv")
670
        Prevalence1 <- Prevalence
671
        library(dplyr)
672
673
       ##clean data and make new variables
674
675
       Prevalence2 <- Prevalence1 %>% filter(BW Z Score <= 1.282)
676
       Prevalence3 <- Prevalence2 %>% mutate(SGA = case when (BW Z Score < -1.282 ~ '1', BW Z Score
677
       >= -1.282 ~ '0'))
678
       Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
679
       Prevalence4$MA <- as.factor(ifelse(Prevalence4$MaternalAge < 20, "10-19".
680
       ifelse(Prevalence4$MaternalAge < 30, "20-29", ifelse(Prevalence4$MaternalAge < 40, "30-39",
681
       ifelse(Prevalence4$MaternalAge < 50, "40-49", "50-60")))))
682
       Prevalence4$Any Anom <- as.factor(ifelse(Prevalence4$Any Anom == "AG", "Genital",
683
       ifelse(Prevalence4$Any_Anom == "CAKUT", "Renal", ifelse(Prevalence4$Any_Anom == "CHD",
684
       "Cardiac", ifelse(Prevalence4$Any Anom == "CNS", "Neurological", ifelse(Prevalence4$Any Anom ==
685
       "GI", "Gastrointestinal", ifelse(Prevalence4$Any Anom == "Pulm", "Pulmonary",
686
       ifelse(Prevalence4$Any_Anom == "Hydrops", "Hydrops", ifelse(Prevalence4$Any_Anom == "Multiple",
687
       "Multiple", "Absent"))))))))
688
       Prevalence4$DY <- as.factor(ifelse(Prevalence4$DischargeYear < 2005, "2000 to 2004",
689
       ifelse(Prevalence4$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4$DischargeYear < 2015,
       "2010 to 2014", "2015 to 2020"))))
690
691
692
       ##load packages
693
694
       library(Hmisc)
695
       library(expss)
696
       library(qtsummary)
697
       library(forestmodel)
698
       library(lme4)
699
700
       ##label data
701
702
       Prevalence4$DischargeYear <- factor(Prevalence4$DischargeYear)
703
       Prevalence4$Race <- factor(Prevalence4$Race)
704
705
       Prevalence4$Race <- relevel(Prevalence4$Race, ref = "White")
706
       Prevalence4$SGA <-factor(Prevalence4$SGA)
707
       Prevalence4$Race <- factor(Prevalence4$Race)
708
       Prevalence4$Sex <- factor(Prevalence4$Sex)
709
       Prevalence4$Any_Anom <- factor(Prevalence4$Any_Anom)
710
       Prevalence4$MA <- factor(Prevalence4$MA)
711
       Prevalence4$DY <- factor(Prevalence4$DY)
712
713
       label(Prevalence4$MA) <- "Maternal Age (years)"
714
       label(Prevalence4$Race) <- "Race and Ethnicity"
715
       label(Prevalence4$Genetic) <- "Genetic Disorder"
716
       label(Prevalence4$Any Anom) <- "Congenital Anomaly"
717
       label(Prevalence4$DY) <- "Discharge Year"
718
719
       ##multiple variable logistic regression model
720
       LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any Anom, data = Prevalence4, family =
721
       "binomial")
722
       ##table depiction of model
```

```
723
       forest model(LogReg3, factor separate line = FALSE)
724
725
       ####Figure 2:
726
727
       ##Load data
728
729
       setwd("/Users/Miles/Desktop")
730
       Outcome <- read.csv("Outcome Update GxDx.csv")
731
       Outcome1 <- Outcome
732
       library(dplyr)
733
734
       ##data preparation
735
736
       Outcome2 <- Outcome1 %>% filter(BW Z Score <= 1.282)
737
       Outcome3 <- Outcome2 %>% mutate(SGA = case when (BW Z Score < -1.282 ~ '1', BW Z Score >= -
738
       1.282 \sim '0')
739
       Outcome4 <- Outcome3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
740
       Outcome5 <- Outcome4 %>% filter(SGA == "1")
741
       Outcome5$DY <- as.factor(ifelse(Outcome5$DischargeYear < 2005, "2000 to 2004",
742
       ifelse(Outcome5$DischargeYear < 2010, "2005 to 2009", ifelse(Outcome5$DischargeYear < 2015, "2010
743
       to 2014", "2015 to 2020"))))
744
       Outcome6 <- Outcome5 %>% mutate(AntSter = ifelse(Antenatal.Steroids == "0", "No", "Yes"))
745
       Outcome7 <- Outcome6 %>% mutate(MV72 = ifelse(MVD0.2 == "N", "No", "Yes"))
746
       Outcome8 <- Outcome7 %>% filter(Deliv Mode == "Cesarean Section" | Deliv Mode == "Vaginal
747
       Delivery")
748
749
       ##load required packages
750
751
       library(expss)
752
       library(gtsummary)
753
       library(forestmodel)
754
       library(lme4)
       library(Hmisc)
755
756
757
       ##Label data
758
        Outcome8$Sex <- factor(Outcome8$Sex)
759
760
        Outcome8$Race <- factor(Outcome8$Race)
761
        Outcome8$AntSter <- factor(Outcome8$AntSter)
762
        Outcome8$CritIllorDeath <- factor(Outcome8$CritIllorDeath)
763
        Outcome8$MV72 <- factor(Outcome8$MV72)
764
        Outcome8$DY <- factor(Outcome8$DY)
765
766
        Outcome8$Sex <- relevel(Outcome8$Sex, ref = "Female")
767
        Outcome8$Race <- relevel(Outcome8$Race, ref = "White")
768
769
       label(Outcome8$AntSter) <- "Antenatal Steroids"
770
       label(Outcome8$Race) <- "Race and Ethnicity"
771
       label(Outcome8$Genetic) <- "Genetic Disorder"
772
       label(Outcome8$Any Anom) <- "Congenital Anomaly"
773
       label(Outcome8$DY) <- "Discharge Year"
774
       label(Outcome8$MV72) <- "MV within 72 Hours"
775
       label(Outcome8$GA) <- "Gestational Age (weeks)"
776
       label(Outcome8$BW Z Score) <- "Birth Weight (Z-score)"
777
```

```
778
       ## multiple variable logistic regression model
779
780
       LogReg <- glm(CritlllorDeath ~ AntSter + Sex + Race + GA + BW Z Score + Deliv Mode + DY + MV72
781
       + Genetic + Any Anom, data = Outcome8, family = "binomial")
782
783
       ##table depiction of model
784
785
       forest model(LogReg, factor separate line = FALSE)
786
787
       ####Figure 3:
788
789
       ##load data
790
791
       setwd("/Users/Miles/Desktop")
792
       Prevalence <- read.csv("MA V Prev per 100 Garphing.csv")
793
       Prevalence1 <- Prevalence
794
795
       ##uplaod required packages
796
797
       library(dplyr)
798
       library("ggplot2")
799
800
801
       ##define and make plot
802
803
       df <- ggplot(Prevalence1, aes(MA, Prev Per 100)) + geom point() + geom errorbar(aes(ymin =
804
       Low per 100, ymax = Upp per <math>100))
805
806
       df + geom_point() + scale x_continuous(breaks=seg(0, 60, 5)) + labs (x = 'Maternal Age (Years)', y =
807
       'SGA Prevalence per 100 Preterm Births') + theme bw() + theme(panel.border = element blank(),
808
       panel.grid.major = element blank(),
809
                                                                                     panel.grid.minor =
810
       element blank(), axis.line = element line(colour = "black"))
811
812
       ####Running a linear regression
813
       Reg <- Im(Prev per 100 ~ MA, data = MA V Prev per 100 Graphing.csv)
814
       ##Review the results
815
       Summary(Reg)
816
817
818
       ####Supplemental table 1
819
       ##Inport Data
820
821
       setwd("/Users/Miles/Desktop")
822
       GxDx <- read.csv("Updated GxDx SGA.csv")
823
824
       ##Upload Packages
```

```
825
826
       library(dplvr)
827
       library(tidyverse)
828
       library(pixiedust)
829
       library(kableExtra)
830
       library(webshot)
831
832
       ##Make Table Backend
833
834
       GxDx2 <- replace(GxDx, is.na(GxDx), "")
835
836
       tbl3 <- dust(GxDx2)
837
838
839
       ##Make the Table
840
841
       tbl3 %>%
842
          sprinkle colnames(Genetic.Diagnosis = "Genetic Diagnosis", SGA = "SGA", AGA= "AGA", Crude.OR
843
       = "Crude OR", X95 low = "Low 95 CI", X95 high = "High 95 CI") %>% kable() %>% kable styling()
844
       %>%
845
          kable classic(full width = F, html font = "Arial") %>%
846
          row spec(1,bold=T,hline after = T) %>%
847
          row spec(9,bold=T,hline after = T) %>%
848
          row spec(14,bold=T,hline after = T) %>%
849
          row spec(21.bold=T.hline after = T) %>%
850
       add indent(c(2,3,4,5,6,7,8,10,11,12,13,15,16,17,18,19,20,22,23,24))
851
852
       ####Supplemental Figure 1
853
854
       ## Load package
855
       library(eulerr)
856
857
       ## enter numbers of individuals in interaction of sets
858
       fit1 <- euler(c("CDW"=0, "Fenton" = 0, "NICHD"=68986,
859
                 "CDW&Fenton"=0, "Fenton&NICHD"=3534, "CDW&NICHD"=2866,
860
                 "CDW&Fenton&NICHD"=33451))
861
       ## plot Euler diagram
862
       plot(fit1, quantities = TRUE, legend = TRUE)
863
864
       ####Supplemental Figure 2
865
       ##Same code as Figure 1 but added one line of code in data preparation
866
867
       Prevalence4 <- Prevalence4 %>% filter(BirthNumber == "1")
868
869
       ####Supplemental Figure 3
870
       ##Same code as Figure 2 but added one line of code in data preparation
871
       Outcome8 <- Outcome8 %>% filter(BirthNumber == "1")
872
873
       ####Figure 1 Interaction Test
874
       LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any Anom + Genetic*Any Anom, data =
875
       Prevalence4, family = "binomial")
876
       anova(LogReg3, test='Chisq')
877
       summary(LogReg3)
878
879
       ####Figure 2 Interaction Test
```

880 LogReg5 <- glm(CritlllorDeath ~ Antenatal.Steroids + Sex + Race + GA + MVD0.2 + Any\_Anom + DY + BW\_Z\_Score + Genetic + Deliv\_Mode + Any\_Anom + Genetic\*Any\_Anom, data = Outcome8, family = "binomial")</p>
883 anova(LogReg5, test='Chisq')
884 summary(LogReg5)
885
886
887